Vildalip-M is a combination of Metformin (500 mg) and Vildagliptin (50 mg) formulated for the effective management of type 2 diabetes. Metformin enhances insulin sensitivity and decreases hepatic glucose production while Vildagliptin a DPP-4 inhibitor increases incretin levels promoting insulin secretion in response to meals and lowering glucagon levels. Together these components provide comprehensive glycemic control helping to maintain stable blood sugar levels and reduce the risk of diabetes-related complications.
Reviews
There are no reviews yet.